Page last updated: 2024-08-07 16:15:58
Endothelin receptor type B
An endothelin receptor type B that is encoded in the genome of human. [PRO:WCB, UniProtKB:P24530]
Synonyms
ET-B;
ET-BR;
Endothelin receptor non-selective type
Research
Bioassay Publications (34)
Timeframe | Studies on this Protein(%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 14 (41.18) | 18.2507 |
2000's | 13 (38.24) | 29.6817 |
2010's | 7 (20.59) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Compounds (41)
Drugs with Inhibition Measurements
Drugs with Activation Measurements
Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
bosentan anhydrous | Homo sapiens (human) | Kd | 0.0724 | 1 | 1 |
a 192621 | Homo sapiens (human) | EC50 | 10.0000 | 1 | 0 |
Optimization of the pharmacophore model for 5-HT7R antagonism. Design and synthesis of new naphtholactam and naphthosultam derivatives.Journal of medicinal chemistry, , Dec-18, Volume: 46, Issue:26, 2003
First pharmacophoric hypothesis for 5-HT7 antagonism.Bioorganic & medicinal chemistry letters, , May-15, Volume: 10, Issue:10, 2000
Optimization of the pharmacophore model for 5-HT7R antagonism. Design and synthesis of new naphtholactam and naphthosultam derivatives.Journal of medicinal chemistry, , Dec-18, Volume: 46, Issue:26, 2003
First pharmacophoric hypothesis for 5-HT7 antagonism.Bioorganic & medicinal chemistry letters, , May-15, Volume: 10, Issue:10, 2000
Optimization of the pharmacophore model for 5-HT7R antagonism. Design and synthesis of new naphtholactam and naphthosultam derivatives.Journal of medicinal chemistry, , Dec-18, Volume: 46, Issue:26, 2003
First pharmacophoric hypothesis for 5-HT7 antagonism.Bioorganic & medicinal chemistry letters, , May-15, Volume: 10, Issue:10, 2000
Optimization of the pharmacophore model for 5-HT7R antagonism. Design and synthesis of new naphtholactam and naphthosultam derivatives.Journal of medicinal chemistry, , Dec-18, Volume: 46, Issue:26, 2003
First pharmacophoric hypothesis for 5-HT7 antagonism.Bioorganic & medicinal chemistry letters, , May-15, Volume: 10, Issue:10, 2000
Optimization of the pharmacophore model for 5-HT7R antagonism. Design and synthesis of new naphtholactam and naphthosultam derivatives.Journal of medicinal chemistry, , Dec-18, Volume: 46, Issue:26, 2003
First pharmacophoric hypothesis for 5-HT7 antagonism.Bioorganic & medicinal chemistry letters, , May-15, Volume: 10, Issue:10, 2000
Optimization of the pharmacophore model for 5-HT7R antagonism. Design and synthesis of new naphtholactam and naphthosultam derivatives.Journal of medicinal chemistry, , Dec-18, Volume: 46, Issue:26, 2003
First pharmacophoric hypothesis for 5-HT7 antagonism.Bioorganic & medicinal chemistry letters, , May-15, Volume: 10, Issue:10, 2000
Optimization of the pharmacophore model for 5-HT7R antagonism. Design and synthesis of new naphtholactam and naphthosultam derivatives.Journal of medicinal chemistry, , Dec-18, Volume: 46, Issue:26, 2003
First pharmacophoric hypothesis for 5-HT7 antagonism.Bioorganic & medicinal chemistry letters, , May-15, Volume: 10, Issue:10, 2000
Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.Journal of medicinal chemistry, , 11-21, Volume: 61, Issue:22, 2018
Endothelin-Receptor Antagonists beyond Pulmonary Arterial Hypertension: Cancer and Fibrosis.Journal of medicinal chemistry, , 09-22, Volume: 59, Issue:18, 2016
From bosentan (Tracleer®) to macitentan (Opsumit®): The medicinal chemistry perspective.Bioorganic & medicinal chemistry letters, , 08-01, Volume: 26, Issue:15, 2016
Metabolism study and biological evaluation of bosentan derivatives.European journal of medicinal chemistry, , Oct-04, Volume: 121, 2016
The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist.Journal of medicinal chemistry, , Sep-13, Volume: 55, Issue:17, 2012
Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective Journal of medicinal chemistry, , Jan-02, Volume: 46, Issue:1, 2003
The use of sulfonylamido pyrimidines incorporating an unsaturated side chain as endothelin receptor antagonists.Bioorganic & medicinal chemistry letters, , Mar-10, Volume: 13, Issue:5, 2003
Pyrrolidine-3-carboxylic acids as endothelin antagonists. 2. Sulfonamide-based ETA/ETB mixed antagonists.Journal of medicinal chemistry, , Sep-26, Volume: 40, Issue:20, 1997
Pyrrolidine-3-carboxylic acids as endothelin antagonists. 2. Sulfonamide-based ETA/ETB mixed antagonists.Journal of medicinal chemistry, , Sep-26, Volume: 40, Issue:20, 1997
2,4-Diarylpyrrolidine-3-carboxylic acids--potent ETA selective endothelin receptor antagonists. 1. Discovery of A-127722.Journal of medicinal chemistry, , Mar-01, Volume: 39, Issue:5, 1996
1,3-Diarylindan-2-carboxylic acids, potent and selective non-peptide endothelin receptor antagonists.Journal of medicinal chemistry, , May-27, Volume: 37, Issue:11, 1994
Pyrrolidine-3-carboxylic acids as endothelin antagonists. 3. Discovery of a potent, 2-nonaryl, highly selective ETA antagonist (A-216546).Journal of medicinal chemistry, , Aug-13, Volume: 41, Issue:17, 1998
2,4-Diarylpyrrolidine-3-carboxylic acids--potent ETA selective endothelin receptor antagonists. 1. Discovery of A-127722.Journal of medicinal chemistry, , Mar-01, Volume: 39, Issue:5, 1996
Pyrrolidine-3-carboxylic acids as endothelin antagonists. 5. Highly selective, potent, and orally active ET(A) antagonists.Journal of medicinal chemistry, , Nov-08, Volume: 44, Issue:23, 2001
Design, synthesis, and activity of a series of pyrrolidine-3-carboxylic acid-based, highly specific, orally active ET(B) antagonists containing a diphenylmethylamine acetamide side chain.Journal of medicinal chemistry, , Sep-09, Volume: 42, Issue:18, 1999
From bosentan (Tracleer®) to macitentan (Opsumit®): The medicinal chemistry perspective.Bioorganic & medicinal chemistry letters, , 08-01, Volume: 26, Issue:15, 2016
The design and synthesis of a novel series of indole derived selective ET(A) antagonists.Bioorganic & medicinal chemistry letters, , Jan-21, Volume: 12, Issue:2, 2002
Pyrrolidine-3-carboxylic acids as endothelin antagonists. 3. Discovery of a potent, 2-nonaryl, highly selective ETA antagonist (A-216546).Journal of medicinal chemistry, , Aug-13, Volume: 41, Issue:17, 1998
Pyrrolidine-3-carboxylic acids as endothelin antagonists. 2. Sulfonamide-based ETA/ETB mixed antagonists.Journal of medicinal chemistry, , Sep-26, Volume: 40, Issue:20, 1997
Discovery, modeling, and human pharmacokinetics of N-(2-acetyl-4,6-dimethylphenyl)-3-(3,4-dimethylisoxazol-5-ylsulfamoyl)thiophene-2-carboxamide (TBC3711), a second generation, ETA selective, and orally bioavailable endothelin antagonist.Journal of medicinal chemistry, , Apr-08, Volume: 47, Issue:8, 2004
Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist.Journal of medicinal chemistry, , May-23, Volume: 40, Issue:11, 1997
Endothelin-Receptor Antagonists beyond Pulmonary Arterial Hypertension: Cancer and Fibrosis.Journal of medicinal chemistry, , 09-22, Volume: 59, Issue:18, 2016
Discovery of IRL 3461: a novel and potent endothelin antagonist with balanced ETA/ETB affinity.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 8, Issue:16, 1998
From bosentan (Tracleer®) to macitentan (Opsumit®): The medicinal chemistry perspective.Bioorganic & medicinal chemistry letters, , 08-01, Volume: 26, Issue:15, 2016
Pyrrolidine-3-carboxylic acids as endothelin antagonists. 3. Discovery of a potent, 2-nonaryl, highly selective ETA antagonist (A-216546).Journal of medicinal chemistry, , Aug-13, Volume: 41, Issue:17, 1998
Optimization of the pharmacophore model for 5-HT7R antagonism. Design and synthesis of new naphtholactam and naphthosultam derivatives.Journal of medicinal chemistry, , Dec-18, Volume: 46, Issue:26, 2003
First pharmacophoric hypothesis for 5-HT7 antagonism.Bioorganic & medicinal chemistry letters, , May-15, Volume: 10, Issue:10, 2000
From bosentan (Tracleer®) to macitentan (Opsumit®): The medicinal chemistry perspective.Bioorganic & medicinal chemistry letters, , 08-01, Volume: 26, Issue:15, 2016
Novel benzo[1,4]diazepin-2-one derivatives as endothelin receptor antagonists.Journal of medicinal chemistry, , May-20, Volume: 47, Issue:11, 2004
Selective optimization of side activities: another way for drug discovery.Journal of medicinal chemistry, , Mar-11, Volume: 47, Issue:6, 2004
Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective Journal of medicinal chemistry, , Jan-02, Volume: 46, Issue:1, 2003
Biphenylsulfonamide endothelin receptor antagonists. Part 3: structure-activity relationship of 4'-heterocyclic biphenylsulfonamides.Bioorganic & medicinal chemistry letters, , Feb-25, Volume: 12, Issue:4, 2002
Biphenylsulfonamide endothelin receptor antagonists. 2. Discovery of 4'-oxazolyl biphenylsulfonamides as a new class of potent, highly selective ET(A) antagonists.Journal of medicinal chemistry, , Aug-10, Volume: 43, Issue:16, 2000
Butenolide endothelin antagonists with improved aqueous solubility.Journal of medicinal chemistry, , Jun-17, Volume: 42, Issue:12, 1999
Endothelin antagonists: evaluation of 2,1,3-benzothiadiazole as a methylendioxyphenyl bioisoster.Bioorganic & medicinal chemistry letters, , Jan-06, Volume: 8, Issue:1, 1998
Structure-activity relationships in a series of orally active gamma-hydroxy butenolide endothelin antagonists.Journal of medicinal chemistry, , Mar-28, Volume: 40, Issue:7, 1997
2,4-Diarylpyrrolidine-3-carboxylic acids--potent ETA selective endothelin receptor antagonists. 1. Discovery of A-127722.Journal of medicinal chemistry, , Mar-01, Volume: 39, Issue:5, 1996
Discovery of a novel series of orally active non-peptide endothelin-A (ETA) receptor-selective antagonists.Journal of medicinal chemistry, , Apr-14, Volume: 38, Issue:8, 1995
Endothelin-Receptor Antagonists beyond Pulmonary Arterial Hypertension: Cancer and Fibrosis.Journal of medicinal chemistry, , 09-22, Volume: 59, Issue:18, 2016
Discovery and synthesis of (S)-3-[2-(3,4-dimethoxyphenyl)ethoxy]-2- (4,6-dimethylpyrimidin-2-yloxy)-3,3-diphenylpropionic acid (LU 302872), a novel orally active mixed ET(A)/ET(B) receptor antagonist.Journal of medicinal chemistry, , Aug-12, Volume: 42, Issue:16, 1999
From bosentan (Tracleer®) to macitentan (Opsumit®): The medicinal chemistry perspective.Bioorganic & medicinal chemistry letters, , 08-01, Volume: 26, Issue:15, 2016
The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist.Journal of medicinal chemistry, , Sep-13, Volume: 55, Issue:17, 2012
Pyrrolidine-3-carboxylic acids as endothelin antagonists. 3. Discovery of a potent, 2-nonaryl, highly selective ETA antagonist (A-216546).Journal of medicinal chemistry, , Aug-13, Volume: 41, Issue:17, 1998
Discovery of a novel series of orally active non-peptide endothelin-A (ETA) receptor-selective antagonists.Journal of medicinal chemistry, , Apr-14, Volume: 38, Issue:8, 1995
From bosentan (Tracleer®) to macitentan (Opsumit®): The medicinal chemistry perspective.Bioorganic & medicinal chemistry letters, , 08-01, Volume: 26, Issue:15, 2016
The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist.Journal of medicinal chemistry, , Sep-13, Volume: 55, Issue:17, 2012
Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells.Bioorganic & medicinal chemistry letters, , Mar-15, Volume: 23, Issue:6, 2013
Design of a functional hexapeptide antagonist of endothelin.Journal of medicinal chemistry, , Aug-21, Volume: 35, Issue:17, 1992
Optimization of the pharmacophore model for 5-HT7R antagonism. Design and synthesis of new naphtholactam and naphthosultam derivatives.Journal of medicinal chemistry, , Dec-18, Volume: 46, Issue:26, 2003
First pharmacophoric hypothesis for 5-HT7 antagonism.Bioorganic & medicinal chemistry letters, , May-15, Volume: 10, Issue:10, 2000
Enables
This protein enables 4 target(s):
Target | Category | Definition |
endothelin receptor activity | molecular function | Combining with endothelin and transmitting the signal across the membrane by activating an associated G-protein; promotes the exchange of GDP for GTP on the alpha subunit of a heterotrimeric G-protein complex. [GOC:bf, GOC:dph, GOC:signaling, IUPHAR_GPCR:1283, IUPHAR_RECEPTOR:2263, IUPHAR_RECEPTOR:2265] |
protein binding | molecular function | Binding to a protein. [GOC:go_curators] |
peptide hormone binding | molecular function | Binding to a peptide with hormonal activity in animals. [GOC:jl, ISBN:0198506732] |
type 1 angiotensin receptor binding | molecular function | Binding to a type 1 angiotensin receptor. [GOC:mah, GOC:nln] |
Located In
This protein is located in 2 target(s):
Target | Category | Definition |
plasma membrane | cellular component | The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. [ISBN:0716731363] |
nuclear membrane | cellular component | Either of the lipid bilayers that surround the nucleus and form the nuclear envelope; excludes the intermembrane space. [GOC:mah, GOC:pz] |
Active In
This protein is active in 1 target(s):
Target | Category | Definition |
plasma membrane | cellular component | The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. [ISBN:0716731363] |
Involved In
This protein is involved in 52 target(s):
Target | Category | Definition |
negative regulation of transcription by RNA polymerase II | biological process | Any process that stops, prevents, or reduces the frequency, rate or extent of transcription mediated by RNA polymerase II. [GOC:go_curators, GOC:txnOH] |
neural crest cell migration | biological process | The characteristic movement of cells from the dorsal ridge of the neural tube to a variety of locations in a vertebrate embryo. [GOC:ascb_2009, GOC:dph, GOC:tb, ISBN:0878932437] |
positive regulation of protein phosphorylation | biological process | Any process that activates or increases the frequency, rate or extent of addition of phosphate groups to amino acids within a protein. [GOC:hjd] |
renin secretion into blood stream | biological process | The regulated release of renin into the blood stream by juxtoglomerular cells. [ISBN:0721643949] |
regulation of heart rate | biological process | Any process that modulates the frequency or rate of heart contraction. [GOC:dph, GOC:tb, PMID:10358008] |
regulation of pH | biological process | Any process involved in the maintenance of an internal equilibrium of hydrogen ions, thereby modulating the internal pH, within an organism or cell. [GOC:dph, GOC:go_curators, GOC:tb] |
cell surface receptor signaling pathway | biological process | The series of molecular signals initiated by an extracellular ligand binding to a receptor located on the cell surface. The pathway ends with regulation of a downstream cellular process, e.g. transcription. [GOC:signaling] |
negative regulation of adenylate cyclase activity | biological process | Any process that stops, prevents, or reduces the frequency, rate or extent of adenylate cyclase activity. [GOC:go_curators] |
phospholipase C-activating G protein-coupled receptor signaling pathway | biological process | A G protein-coupled receptor signaling pathway in which the signal is transmitted via the activation of phospholipase C (PLC) and a subsequent increase in the intracellular concentration of inositol trisphosphate (IP3) and diacylglycerol (DAG). [GOC:dph, GOC:mah, GOC:signaling, GOC:tb, ISBN:0815316194] |
positive regulation of cytosolic calcium ion concentration | biological process | Any process that increases the concentration of calcium ions in the cytosol. [GOC:ai] |
nervous system development | biological process | The process whose specific outcome is the progression of nervous tissue over time, from its formation to its mature state. [GOC:dgh] |
peripheral nervous system development | biological process | The process whose specific outcome is the progression of the peripheral nervous system over time, from its formation to the mature structure. The peripheral nervous system is one of the two major divisions of the nervous system. Nerves in the PNS connect the central nervous system (CNS) with sensory organs, other organs, muscles, blood vessels and glands. [GOC:go_curators, UBERON:0000010] |
posterior midgut development | biological process | The process whose specific outcome is the progression of the posterior midgut over time, from its formation to the mature structure. [GOC:go_curators] |
positive regulation of cell population proliferation | biological process | Any process that activates or increases the rate or extent of cell proliferation. [GOC:go_curators] |
gene expression | biological process | The process in which a gene's sequence is converted into a mature gene product (protein or RNA). This includes the production of an RNA transcript and its processing, as well as translation and maturation for protein-coding genes. [GOC:txnOH-2018, PMID:25934543, PMID:31580950] |
negative regulation of neuron maturation | biological process | Any process that stops, prevents, or reduces the frequency, rate or extent of neuron maturation. [GOC:ef] |
response to organic cyclic compound | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an organic cyclic compound stimulus. [GOC:ef] |
vein smooth muscle contraction | biological process | A process in which force is generated within smooth muscle tissue, resulting in a change in muscle geometry. This process occurs in the vein. Force generation involves a chemo-mechanical energy conversion step that is carried out by the actin/myosin complex activity, which generates force through ATP hydrolysis. The vein is a vessel carrying blood away from the capillary beds. [GOC:mtg_muscle, MA:0000715, MSH:D014680] |
calcium-mediated signaling | biological process | Any intracellular signal transduction in which the signal is passed on within the cell via calcium ions. [GOC:signaling] |
cGMP-mediated signaling | biological process | An intracellular signaling cassette that starts with production of cyclic GMP (cGMP), and ends with activation of downstream effectors that further transmit the signal within the cell. [GOC:signaling] |
heparin metabolic process | biological process | The chemical reactions and pathways involving heparin, any member of a group of glycosaminoglycans found mainly as an intracellular component of mast cells. They are similar to heparan sulfates but are of somewhat higher average Mr (6000-20000) and contain fewer N-acetyl groups and more N-sulfate and O-sulfate groups; they may be attached in the same manner to protein, forming proteoglycans. They consist predominantly of alternating alpha-(1->4)-linked D-galactose and N-acetyl-D-glucosamine-6-sulfate residues. [GOC:mah, ISBN:0198506732] |
melanocyte differentiation | biological process | The process in which a relatively unspecialized cell acquires specialized features of a melanocyte. [GOC:mah] |
regulation of fever generation | biological process | Any process that modulates the rate or extent of fever generation. [GOC:add, GOC:dph, GOC:tb] |
aldosterone metabolic process | biological process | The chemical reactions and pathways involving aldosterone, a corticosteroid hormone that is produced by the zona glomerulosa of the adrenal cortex and regulates salt (sodium and potassium) and water balance. [PMID:16527843] |
enteric smooth muscle cell differentiation | biological process | The process in which a relatively unspecialized cell acquires specialized features of a smooth muscle cell of the intestine. [CL:0002504, GOC:BHF] |
positive regulation of urine volume | biological process | Any process that increases the amount of urine excreted from the body over a unit of time. [GOC:mtg_25march11, GOC:yaf] |
renal sodium excretion | biological process | The elimination of sodium ions from peritubular capillaries (or surrounding hemolymph in invertebrates) into the renal tubules to be incorporated subsequently into the urine. [GOC:mtg_25march11, GOC:yaf, PMID:25287933] |
epithelial fluid transport | biological process | The directed movement of fluid across epithelia. [GOC:jl, PMID:11390830] |
vasoconstriction | biological process | A decrease in the diameter of blood vessels, especially arteries, due to constriction of smooth muscle cells that line the vessels, and usually causing an increase in blood pressure. [GOC:pr, ISBN:0192800752] |
vasodilation | biological process | An increase in the internal diameter of blood vessels, especially arterioles or capillaries, due to relaxation of smooth muscle cells that line the vessels, and usually resulting in a decrease in blood pressure. [GOC:pr, ISBN:0192800981] |
negative regulation of apoptotic process | biological process | Any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptotic process. [GOC:jl, GOC:mtg_apoptosis] |
positive regulation of canonical NF-kappaB signal transduction | biological process | Any process that activates or increases the frequency, rate or extent of a canonical NF-kappaB signaling cascade. [GOC:jl] |
macrophage chemotaxis | biological process | The movement of a macrophage in response to an external stimulus. [GOC:jid] |
response to pain | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a pain stimulus. Pain stimuli cause activation of nociceptors, peripheral receptors for pain, include receptors which are sensitive to painful mechanical stimuli, extreme heat or cold, and chemical stimuli. [GOC:jid, PMID:10203867, PMID:12723742, PMID:12843304, Wikipedia:Pain] |
enteric nervous system development | biological process | The process whose specific outcome is the progression of the enteric nervous system over time, from its formation to the mature structure. The enteric nervous system is composed of two ganglionated neural plexuses in the gut wall which form one of the three major divisions of the autonomic nervous system. The enteric nervous system innervates the gastrointestinal tract, the pancreas, and the gallbladder. It contains sensory neurons, interneurons, and motor neurons. Thus the circuitry can autonomously sense the tension and the chemical environment in the gut and regulate blood vessel tone, motility, secretions, and fluid transport. The system is itself governed by the central nervous system and receives both parasympathetic and sympathetic innervation. [FMA:66070, GOC:jid, GOC:sr] |
regulation of epithelial cell proliferation | biological process | Any process that modulates the frequency, rate or extent of epithelial cell proliferation. [GOC:ai] |
negative regulation of protein metabolic process | biological process | Any process that stops, prevents, or reduces the frequency, rate or extent of chemical reactions and pathways involving a protein. [GOC:ai] |
canonical Wnt signaling pathway | biological process | A type of Wnt signaling pathway in which Wnt binding to its receptor on the surface of a target cell results in the by propagation of the molecular signals via beta-catenin, and end with a change in transcription of target genes. In this pathway, the activated receptor signals via downstream effectors that result in the inhibition of beta-catenin phosphorylation, thereby preventing degradation of beta-catenin. Stabilized beta-catenin can then accumulate and travel to the nucleus to trigger changes in transcription of target genes. [PMID:11532397, PMID:19619488] |
positive regulation of penile erection | biological process | Any process that increases the rate, frequency or extent of penile erection. Penile erection is the hardening, enlarging and rising of the penis which often occurs in the sexually aroused male and enables sexual intercourse. Achieved by increased inflow of blood into the vessels of erectile tissue, and decreased outflow. [GOC:dph, GOC:tb] |
establishment of endothelial barrier | biological process | The establishment of a barrier between endothelial cell layers, such as those in the brain, lung or intestine, to exert specific and selective control over the passage of water and solutes, thus allowing formation and maintenance of compartments that differ in fluid and solute composition. [GOC:dph] |
renal sodium ion absorption | biological process | A renal system process in which sodium ions are taken up from the collecting ducts and proximal and distal loops of the nephron. In non-mammalian species, absorption may occur in related structures. [GOC:dph, GOC:mah] |
calcium ion transmembrane transport | biological process | A process in which a calcium ion is transported from one side of a membrane to the other by means of some agent such as a transporter or pore. [GOC:mah] |
cellular response to lipopolysaccharide | biological process | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a lipopolysaccharide stimulus; lipopolysaccharide is a major component of the cell wall of gram-negative bacteria. [GOC:mah] |
protein transmembrane transport | biological process | The process in which a protein is transported across a membrane. [GOC:mah, GOC:vw] |
podocyte differentiation | biological process | The process in which a relatively unspecialized cell acquires specialized features of a glomerular visceral epithelial cell. A glomerular visceral epithelial cell is a specialized epithelial cell that contains 'feet' that interdigitate with the 'feet' of other glomerular epithelial cells. [GOC:mtg_kidney_jan10] |
endothelin receptor signaling pathway | biological process | A G protein-coupled receptor signaling pathway initiated by endothelin binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription. [GOC:bf, GOC:BHF, GOC:mtg_cardiac_conduct_nov11, PMID:10977869] |
renal albumin absorption | biological process | A renal system process in which albumin is taken up from the collecting ducts, glomerulus and proximal and distal loops of the nephron. [GOC:yaf, PMID:18431508] |
neuroblast migration | biological process | The orderly movement of a neuroblast from one site to another, often during the development of a multicellular organism or multicellular structure. A neuroblast is any cell that will divide and give rise to a neuron. [CL:0000031, GOC:jc, PMID:15543145] |
chordate pharynx development | biological process | The process whose specific outcome is the progression of cordate pharynx over time, from its formation to the mature structure. [PMID:23020903] |
response to sodium phosphate | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a sodium phosphate stimulus. [GO_REF:0000071, GOC:TermGenie, PMID:24625659] |
response to endothelin | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an endothelin stimulus. Endothelin is any of three secretory vasoconstrictive peptides (endothelin-1, -2, -3). [PMID:16365184] |
developmental pigmentation | biological process | The developmental process that results in the deposition of coloring matter in an organism, tissue or cell. [ISBN:0582227089] |